The International Journal of Tuberculosis and Lung Disease

Blood biomarkers in chronic obstructive pulmonary disease: is there a life beyond plasma fibrinogen?
pp. 963-964(2)
Author: Sin, D. D.

Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB
pp. 965-971(7)
Authors: Van Deun, A.; Decroo, T.; Kuaban, C.; Noeske, J.; Piubello, A.; Aung, K. J. M.; Rieder, H. L.

Indo-Oceanic Mycobacterium tuberculosis strains from Thailand associated with higher mortality
pp. 972-979(8)
Authors: Smittipat, N.; Miyahara, R.; Juthayothin, T.; Billamas, P.; Dokladda, K.; Imsanguan, W.; Intralawan, D.; Rukseree, K.; Jaitrong, S.; Chaiyasirinroje, B.; Wongjai, J.; Disratthakit, A.; Chaiprasert, A.; Nedsuwan, S.; Mahasirimongkol, S.; Toyo-oka, L.; Tokunaga, K.; Yamada, N.; Palittapongarnpim, P.; Yanai, H.

Evaluation of miLINC to shorten time to treatment for rifampicin-resistant Mycobacterium tuberculosis
pp. 980-988(9)
Authors: Farley, J. E.; McKenzie-White, J.; Bollinger, R.; Hong, H.; Lowensen, K.; Chang, L. W.; Stamper, P.; Berrie, L.; Olsen, F.; Isherwood, L.; Ndjeka, N.; Stevens, W.

Serial T-SPOT.TB in household contacts of tuberculosis patients: a 6-year observational study in China
pp. 989-995(7)
Authors: Zhang, H-C.; Ruan, Q-L.; Wu, J.; Zhang, S.; Yu, S-L.; Wang, S.; Gao, Y.; Wang, F-F.; Shao, L-Y.; Zhang, W-H.

Progress in global rollout of new multidrug-resistant tuberculosis treatments
pp. 996-999(4)
Authors: Held, K.; McAnaw, S.; Chiang, C-Y.; Trebucq, A.; Horsburgh, C. R.

Trends of tuberculosis rates before and after the declaration as a public health emergency in Japan, 1992–2006
pp. 1000-1004(5)
Authors: Ota, M.; Uchimura, K.

Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia
pp. 1005-1011(7)
Authors: Buziashvili, M.; Mirtskhulava, V.; Kipiani, M.; Blumberg, H. M.; Baliashvili, D.; Magee, M. J.; Furin, J. J.; Tukvadze, N.; Kempker, R. R.

Rifampin pharmacokinetics in tuberculosis-diabetes mellitus patients: a pilot study from Baja California, Mexico
pp. 1012-1016(5)
Authors: Perea-Jacobo, R.; Muñiz-Salazar, R.; Laniado-Laborín,, R.; Cabello-Pasini,, A.; Zenteno-Cuevas,, R.; Ochoa-Terán, A.

Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting
pp. 1017-1023(7)
Authors: Hughes, J.; Reuter, A.; Chabalala, B.; Isaakidis, P.; Cox, H.; Mohr, E.

Tuberculosis screening in outpatient healthcare workers: lessons from a high-income, low TB burden country
pp. 1024-1028(5)
Authors: Di Bella, S.; Siroka, A.; Antonello, R. M.; Zignol, M.; Maschio, M.; Tominz, R.; Cirillo, D.; Migliori, G. B.; Confalonieri, M.; Raviglione, M.; Luzzati, R.

To be or not to be hospitalised with tuberculosis in Portugal
pp. 1029-1034(6)
Authors: Galego, M. A.; Santos, J. V.; Viana, J.; Freitas, A.; Duarte, R.

Association of plasma fibrinogen concentrations and blood eosinophil counts with clinical phenotypes of COPD
pp. 1035-1041(7)
Authors: Hyun, D-G.; Lee, J. H.; Oh, Y-M.; Lee, S. W.; Lee, S. D.; Lee, J. S.

A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care
pp. 1042-1042(1)
Authors: Vanino, E.; Tadolini, M.; Attard, L.; Cascavilla, A.; Pea, F.; Viale, P.

Expand the RRDR hotspot to improve GeneXpert results
pp. 1043-1043(1)
Authors: Mishra, B.; Mohapatra, P. R.

Ensuring that Xpert^® MTB/RIF is used to its maximum potential
pp. 1043-1044(2)
Authors: Harries, A. D.; Timire, C.; Takarinda, K. C.; Sandy, C.

Assessing and managing pulmonary impairment in those who have completed TB treatment in programmatic settings
pp. 1044-1045(2)
Authors: Harries, A. D.; Chakaya, J. M.